BISL LIMITED
Company number 03231094 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: BISL Limited
Company No. 03231094 | Incorporated 30 July 1996 | Peterborough, UK
Patient chart: BISL Limited is a ~29-year-old private limited company operating in business support services (SIC 82990). Formerly Budget Insurance Services Limited, it has a long heritage in insurance distribution and now sits within the Markerstudy Group, having been passed from BGL Group ownership. Let's take its vitals.
1. Financial Health Score: A- (Provisional — Structural & Compliance Health)
Every observable vital sign is green: spotless filing compliance, substantial capitalisation, stable group ownership, and no insolvency or governance red flags. The grade is provisional for one important reason — the filed financial statements themselves (the "blood panel") are not included in this dataset, so profitability, liquidity, and solvency cannot yet be measured. Think of this as a patient with a strong pulse, clear airways, and excellent attendance at check-ups — but we still need the lab results before declaring full fitness.
2. Key Vital Signs
| Vital Sign | Reading | Medical Interpretation |
|---|---|---|
| Company status | Active; no insolvency flags | Patient is conscious and breathing — no administration, receivership, or liquidation machinery attached |
| Accounts filing | Full accounts to 31 Dec 2025; next due 30 Sept 2027; not overdue | Regular check-ups attended punctually — filing well inside deadlines suggests disciplined administration |
| Confirmation statement | Current to 27 Oct 2025; next due 10 Nov 2026 | Identity records in order |
| Accounts type | Full (unabridged) accounts | The entity files complete statements rather than small-company exemptions — indicating a substantial business |
| Share capital | £18,000,000 | Strong bone structure — a deep permanent capital base, typical of a capitalised insurance intermediary |
| Trading history | ~29 years since 1996 | A long-lived patient that has survived multiple economic cycles and ownership changes |
| Ownership (PSC) | Markerstudy Group Ltd (>75% shares & votes) | A clean "transplant" from BGL Group — group backing provides strength, but also dependency |
| Board | 5 directors + company secretary; one routine resignation (Feb 2026) | Healthy organ function; normal cell turnover, no signs of boardroom haemorrhaging |
| Director conduct | No disqualification records | No history of malpractice |
Symptoms analysis: In medicine, the absence of symptoms is itself diagnostic. There are no distress symptoms here: no overdue filings (the corporate equivalent of missed appointments), no insolvency events, no disqualifications, and no sudden exodus of officers. The PSC register shows an ownership transition (BGL → Markerstudy), which is a major corporate event — but the company emerged from it intact, filing on time throughout.
3. Diagnosis
Structurally healthy; financial bloods pending. What the record reveals:
- No symptoms of distress. Filing discipline is excellent, and compliance hygiene is the single best external predictor of a well-run company.
- Group subsidiary, not a standalone organism. BISL shares its circulatory system with Markerstudy Group. This means parent support is likely available in a downturn — but its health is partly tied to the group's.
- Well-capitalised. £18M of share capital is a serious commitment of permanent capital, often held to support regulatory requirements in insurance distribution.
- The honest limitation: without the balance sheet and profit & loss account, we cannot test the three critical organs of financial health — liquidity (can it pay its bills?), profitability (is the heart pumping value?), and solvency (is the body carrying too much debt?). The patient looks well from the outside; the inside needs examination.
4. Prognosis
Favourable, conditional on group health. As a wholly-owned subsidiary, BISL's outlook tracks Markerstudy Group's. Watch items include post-acquisition integration, intra-group funding arrangements, and sector conditions — insurance distribution faces regulatory change (FCA value measures, fair value assessments) and premium-cycle pressures. The company's age, capital, and compliance record suggest resilience, but any assessment of a group subsidiary should always include a look at the parent.
5. Recommendations
- Complete the blood panel. Retrieve the full accounts from Companies House and examine the profit & loss, balance sheet, and — critically — the going concern statement and any parent company support letters.
- Check the group's charts. Review Markerstudy Group's accounts for consolidated health, since BISL depends on the parent's circulatory system.
- Examine related-party balances. Intra-group loans and receivables are the most common place for hidden strain in subsidiary accounts.
- Verify regulatory standing. As an insurance intermediary, BISL will be FCA-regulated — check the FCA Register, which Companies House data does not show.
- Keep monitoring the pulse. Set alerts for future filings, PSC changes, and officer movements. A sudden cluster of resignations or late filings would be an early fever reading.